Quantcast

Industry news that matters to you.  Learn more

Metabolon Enters into Agreement with the Carlos Slim Institute, Patia and Clinica Ruiz for Quantose Prediabetes Test in Mexico

Metabolon, Inc., the world leading metabolomics company recently announced the signing of several exclusive multi-year, royalty-based Research Collaboration and Licensing agreements with Patia Biopharma, a Mexican biotech company working to make personalized preventive medicine a reality in Mexico and Latin America. The Research Collaboration provides Metabolon’s Quantose IR™ technology for use in several Diabetes Prevention Studies in Mexico. The License agreement provides exclusive access in Mexico to Metabolon’s prediabetes test technology for assessing insulin resistance in the general population of Mexico through Patia and Clinica Ruiz’s network of laboratories.

Research by ClinMet Scientific Founder and Colleagues Point to Enzyme that Restores Function in Diabetic Kidney Disease

ClinMet recently announced that researchers from The University of California, San Diego School of Medicine and colleagues have published new findings that could fundamentally change understanding of how diabetes-related diseases develop – and how they might be better treated.

Agile Health Announces New Diabetes Empowerment Program

Agile Health, a mobile healthcare solutions provider, recently announced the release of myAgileLife™, a text messaging based health engagement program designed to help individuals with Type II Diabetes master the behavioral skills necessary to achieve a lifetime of healthier outcomes. Developed in a medical research institute and validated via a soon-to-be-published clinical trial, myAgileLife provides daily support to help program participants affect the foundational changes in lifestyle and self-care behaviors required to successfully manage their diabetes.

ClinMet Metabolomics Platform Offers Unique Insights into Diabetic Kidney Disease

ClinMet recently announced that researchers from The University of California, San Diego School of Medicine have published new metabolomics research that uncovers a novel, characteristic and highly consistent biochemical signature in urine associated with diabetic kidney disease. The findings, which form a foundation of ClinMet’s proprietary Clinical Metabolomics platform, have implications for the identification of clinically useful biomarkers for kidney function and for sharpening drug development and clinical trials related to chronic kidney disease, as well as to diabetes, obesity and cardiovascular disease.

PatientPartner Improves Adherence in First Independent IRB-Approved Clinical Trial of a Mobile Game Application in Diabetes Patients

Breakthrough clinical trial results for “PatientPartner,” a new mobile game application designed by scientists and researchers at CyberDoctor, document for the first time the effectiveness of a story-driven game in changing health behavior and biomarkers. Results of the clinical trial demonstrating increased adherence among patients with diabetes were announced last month at the Health 2.0 Conference, October 2nd, in Santa Clara, CA. The unique, universal, non-disease specific approach allows PatientPartner to be effective in improving adherence in all patient populations.